-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Cytokinetics, Raises Price Target to $113

Benzinga·10/08/2026 14:45:27
Listen to the news
RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and raises the price target from $112 to $113.